I. Bazin

1.3k citations

30 papers · 975 indexed · 1 hit paper · h-index 13

Oncology top 10%
Pulmonary and Respiratory Medicine top 10%
Cancer Research top 5%
Molecular Biology
Surgery

Co-authors: Bohuslav Melichar В. П. Шелепов Samuil R. Umansky Hovsep Melkonyan Г. И. Потапова I. V. Botezatu August Garin A. V. Lichtenstein
Topics: Pancreatic and Hepatic Oncology Research (13 papers)Gastric Cancer Management and Outcomes (10 papers)Colorectal Cancer Treatments and Studies (6 papers)
Cited by: Cancer Research Oncology Gastroenterology
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaAnnals of Oncology
Partner nations: Russia Germany United States

In The Last Decade

I. Bazin

26 papers receiving 958 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

2021 244 citations Uğur Şahin, Ö. Türeci et al. Annals of Oncology profile →

Peers

Countries citing papers authored by I. Bazin

Since Specialization

Citations

This map shows the geographic impact of I. Bazin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Bazin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Bazin more than expected).

Fields of papers citing papers by I. Bazin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Bazin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Bazin. The network helps show where I. Bazin may publish in the future.

Co-authorship network of co-authors of I. Bazin

This figure shows the co-authorship network connecting the top 25 collaborators of I. Bazin. A scholar is included among the top collaborators of I. Bazin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Bazin. I. Bazin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Place of tyrosine kinase inhibitors in the first line of treatment of hepatocellular carcinoma 2024 ·Meditsinskiy sovet = Medical Council ·(unknown),(unknown),А. N. Polyakov,I. Bazin	0
2	Systemic therapy for metastatic pancreatic cancer 2023 ·Malignant tumours ·(unknown),М. Yu. Fedyanin,I. Bazin,И. А. Покатаев,A. Tryakin	0
3	FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinomabreakdown → 2021 ·Annals of Oncology ·Uğur Şahin,Ö. Türeci,Georgy M. Manikhas,Florian Lordick,Andriy Rusyn,Ihor Vynnychenko,Assen Dudov,I. Bazin,Igor Bondarenko,Bohuslav Melichar,Karl Dhaene,Kai Wiechen,Christoph Huber,Daniel Maurus,Ahsan M. Arozullah,J.W. Park,Martin Schüler,S. Al-Batran	244
4	EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment 2019 ·Annals of Oncology ·Meng Su,(unknown),Erika Hitre,(unknown),Li‐Yuan Bai,Zsuzsanna Pápai,Seok Yun Kang,Mikhail Dvorkin,Min‐Hsien Lee,(unknown),(unknown),(unknown),G. Bodoky,Pascal Artru,Jun‐Eul Hwang,I. Bazin,(unknown),Jean‐Baptiste Bachet,Zsolt Horváth,Chirn‐Bin Chang,Johnson Lin	4
5	Combined treatment for locally advanced cholangiocellular liver cancer - the case report 2019 ·SHILAP Revista de lepidopterología ·А. N. Polyakov,(unknown),(unknown),(unknown),I. Bazin,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	0
6	Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial. 2019 ·Journal of Clinical Oncology ·Uğur Şahin,Özlem Türeci,Georgy M. Manikhas,Florian Lordick,Andriy Rusyn,Ihor Vynnychenko,Assen Dudov,I. Bazin,Igor Bondarenko,Bohuslav Melichar,Karl Dhaene,Kai Wiechen,Daniel Maurus,Martin Schüler,Salah‐Eddin Al‐Batran	16
7	Clinical Predictors of Second-Line Chemotherapy Benefit in Patients with Pancreatic Cancer 2017 ·JOP, journal of the pancreas ·И. А. Покатаев,(unknown),A. Tryakin,М. Yu. Fedyanin,I. Bazin,(unknown),(unknown),(unknown),(unknown),(unknown)	2
8	Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma 2016 ·Annals of Oncology ·Martin Schüler,S-E. Al-Batran,Zanete Zvirbule,George Manikhas,Florian Lordick,Andriy Rusyn,Yuriy Vinnyk,Ihor Vynnychenko,Natalia Fadeeva,M. Nechaeva,Assen Dudov,(unknown),(unknown),I. Bazin,Igor Bondarenko,Bohuslav Melichar,Christoph Huber,Ö. Türeci,Uğur Şahin	18
9	220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer 2016 ·Annals of Oncology ·Florian Lordick,Martin Schüler,S-E. Al-Batran,Zanete Zvirbule,G. Manikhas,Andriy Rusyn,Yuriy Vinnyk,Ihor Vynnychenko,Natalia Fadeeva,M. Nechaeva,Assen Dudov,(unknown),(unknown),I. Bazin,Igor Bondarenko,Bohuslav Melichar,Christoph Huber,Uğur Şahin,(unknown)	2
10	Morbidity, mortality, long-term outcomes and sequelae of the treatment of cancer patients in different countries of the world 2016 ·Russian Journal of Oncology ·Avgust M. Garin,I. Bazin	2
11	Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer 2016 ·Annals of Oncology ·T.R. Jeffry Evans,Eric Van Cutsem,Michael J. Moore,I. Bazin,Alexander S. Rosemurgy,G. Bodoky,G. Deplanque,Michelle Harrison,Bohuslav Melichar,Denis Pezet,(unknown),Edwin P. Rock,Chun‐Chi Lin,Lewis C. Strauss,Peter J. O’Dwyer	50
12	FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. 2016 ·Journal of Clinical Oncology ·Salah‐Eddin Al‐Batran,Martin Schüler,Zanete Zvirbule,G. Manikhas,Florian Lordick,Andriy Rusyn,(unknown),Ihor Vynnychenko,Natalia Fadeeva,M. Nechaeva,Assen Dudov,Evgeny Gotovkin,(unknown),I. Bazin,Igor Bondarenko,Bohuslav Melichar,Christian Mueller,Christoph Huber,(unknown),Uğur Şahin	35
13	Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. 2016 ·Journal of Clinical Oncology ·Eric Van Cutsem,Heinz‐Josef Lenz,Junji Furuse,Josep Tabernero,Volker Heinemann,Tatsuya Ioka,I. Bazin,Makoto Ueno,Tibor Csőszi,Harpreet Wasan,Bohuslav Melichar,Petr Karásek,Teresa Macarulla,Carmen Guillén‐Ponce,Ewa Kalinka‐Warzocha,Zsolt Horváth,Hans Prenen,Michael Schlichting,Mehdi Fazal,Johanna C. Bendell	23
14	A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma 2016 ·Annals of Oncology ·Tudor–Eliade Ciuleanu,I. Bazin,Dan Lungulescu,Lucian Miron,Igor Bondarenko,Andrzej Deptała,M. Rodríguez‐Torres,Bruce J. Giantonio,N. L. Fox,Paul Wissel,(unknown),(unknown),Rubana N. Kalyani,Robin Humphreys,Matthew Gribbin,Weijing Sun	39
15	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer. 2015 ·Journal of Clinical Oncology ·Eric Van Cutsem,Manuel Hidalgo,I. Bazin,Jean-Luc Canon,Elena Poddubskaya,Nebojša Manojlović,Michèle Milella,Dejan Radenković,Chris Verslype,(unknown),Lars Damstrup,Pascal Hammel	19
16	[Possibilities of stereotactic radiotherapy in the palliative treatment of patients with pancreatic cancer]. 2015 ·PubMed ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),I. Bazin,(unknown)	1
17	Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC). 2014 ·Journal of Clinical Oncology ·Tudor–Eliade Ciuleanu,I. Bazin,Dan Lungulescu,Lucian Miron,Igor Bondarenko,Andrzej Deptała,M. Rodríguez‐Torres,Bruce J. Giantonio,Weijing Sun,Norma Lynn Fox,Gursel Aktan,Paul Wissel,(unknown),Meichun Ding,Rubana N. Kalyani,Matthew Gribbin	1
18	A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy 2010 ·Annals of Oncology ·(unknown),И. А. Покатаев,(unknown),A. Tryakin,I. Bazin,(unknown),(unknown),A. Garin,Sergei Tjulandin	50
19	[Targeted drugs for the treatment of disseminated colonic cancer]. 2009 ·PubMed ·A. Garin,I. Bazin,(unknown)	1
20	A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer 2007 ·Oncology ·Craig Underhill,David Goldstein,Vera Gorbounova,M. Biakhov,I. Bazin,(unknown),Anwar M. Hossain,J. Blatter,Christopher Kaiser,Doreen Ma	16

About I. Bazin

I. Bazin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 30 papers that have together received 975 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (13 papers), Gastric Cancer Management and Outcomes (10 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Cancer Research (332 citations), Oncology (424 citations) and Gastroenterology (78 citations). I. Bazin has collaborated with scholars based in Russia, Germany and United States. Frequent co-authors include Bohuslav Melichar, В. П. Шелепов, Samuil R. Umansky, Hovsep Melkonyan, Г. И. Потапова, I. V. Botezatu, August Garin, A. V. Lichtenstein, В И Кныш and Igor Bondarenko. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact